BR112015007312A2 - composto, composição farmacêutica, utilização de um composto, método para o tratamento de câncer e invenção - Google Patents
composto, composição farmacêutica, utilização de um composto, método para o tratamento de câncer e invençãoInfo
- Publication number
- BR112015007312A2 BR112015007312A2 BR112015007312A BR112015007312A BR112015007312A2 BR 112015007312 A2 BR112015007312 A2 BR 112015007312A2 BR 112015007312 A BR112015007312 A BR 112015007312A BR 112015007312 A BR112015007312 A BR 112015007312A BR 112015007312 A2 BR112015007312 A2 BR 112015007312A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- treating cancer
- cancer
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261732466P | 2012-12-03 | 2012-12-03 | |
| PCT/EP2013/075219 WO2014086704A1 (en) | 2012-12-03 | 2013-12-02 | Substituted isoxazole amide compounds as inhibitors of stearoyl-coa desaturase 1 (scd1) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015007312A2 true BR112015007312A2 (pt) | 2017-08-08 |
Family
ID=49679539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015007312A BR112015007312A2 (pt) | 2012-12-03 | 2013-12-02 | composto, composição farmacêutica, utilização de um composto, método para o tratamento de câncer e invenção |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9296711B2 (pt) |
| EP (1) | EP2925751A1 (pt) |
| JP (1) | JP2016501212A (pt) |
| KR (1) | KR20150090100A (pt) |
| CN (1) | CN104870444A (pt) |
| BR (1) | BR112015007312A2 (pt) |
| CA (1) | CA2884711A1 (pt) |
| HK (1) | HK1209123A1 (pt) |
| MX (1) | MX2015006754A (pt) |
| RU (1) | RU2015122615A (pt) |
| WO (1) | WO2014086704A1 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11970486B2 (en) | 2016-10-24 | 2024-04-30 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| AU2018205275B2 (en) | 2017-01-06 | 2024-05-02 | Janssen Pharmaceutica Nv | Methods for the treatment of neurological disorders |
| WO2019084157A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES THEREOF |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6251928B1 (en) | 1994-03-16 | 2001-06-26 | Eli Lilly And Company | Treatment of alzheimer's disease employing inhibitors of cathepsin D |
| US5739326A (en) | 1995-12-13 | 1998-04-14 | E. I. Du Pont De Nemours And Company | Heterobicyclic herbicides |
| BRPI0508098A (pt) | 2004-02-27 | 2007-07-17 | Amgen Inc | compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos |
| BRPI0515477A (pt) * | 2004-09-20 | 2008-07-22 | Xenon Pharmaceuticals Inc | derivados heterocìclicos bicìclicos e o uso dos mesmos como inibidores de estaroil-coa-desaturase (scd) |
| EP2316458A1 (en) * | 2004-09-20 | 2011-05-04 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
| TW200633990A (en) | 2004-11-18 | 2006-10-01 | Takeda Pharmaceuticals Co | Amide compound |
| WO2007056366A2 (en) | 2005-11-07 | 2007-05-18 | Irm Llc | Compounds and compositions as ppar modulators |
| DK2474521T3 (en) | 2006-06-19 | 2016-10-31 | Newron Pharm Spa | High-purity 2- [4- (3- and 2-fluorobenzyloxy) benzylamino] propanamides for use as pharmaceuticals and pharmaceutical formulations thus |
| AR064965A1 (es) * | 2007-01-26 | 2009-05-06 | Merck Frosst Canada Inc | Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa |
| JP2011506348A (ja) * | 2007-12-11 | 2011-03-03 | メルク フロスト カナダ リミテツド | ステアロイル−補酵素ａデルタ−９デサチュラーゼの阻害剤としての新規な複素環式芳香族化合物 |
| JP2012528140A (ja) | 2009-05-29 | 2012-11-12 | ファイザー・リミテッド | 新規なグルココルチコイド受容体アゴニスト |
| US20130040951A9 (en) | 2009-08-04 | 2013-02-14 | Takeda Pharmaceutical Company Limited | Prophylactic or therapeutic agent for cancer |
| US9212177B2 (en) | 2009-08-05 | 2015-12-15 | Versitech Limited | Antiviral compounds and methods of making and using thereof |
| WO2011121350A1 (en) | 2010-04-01 | 2011-10-06 | Astrazeneca Ab | 4 -amino -7,8- dihydropyrimido [5, 4 - f] [1, 4] oxazepin- 5 ( 6h) - one based dgat1 inhibitors |
| MX2012013081A (es) | 2010-05-12 | 2013-05-09 | Vertex Pharma | Compuestos utiles como inhibidores de cinasa atr. |
| US8242282B2 (en) | 2010-05-18 | 2012-08-14 | Taipei Medical University | Histone deacetylase inhibitors |
| EP2590972B1 (en) | 2010-07-09 | 2015-01-21 | Pfizer Limited | N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels |
| WO2012025638A1 (en) | 2010-08-27 | 2012-03-01 | Universität des Saarlandes | Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors |
| US20120071516A1 (en) | 2010-09-22 | 2012-03-22 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
-
2013
- 2013-12-02 CA CA2884711A patent/CA2884711A1/en not_active Abandoned
- 2013-12-02 CN CN201380063272.XA patent/CN104870444A/zh active Pending
- 2013-12-02 JP JP2015544492A patent/JP2016501212A/ja active Pending
- 2013-12-02 RU RU2015122615A patent/RU2015122615A/ru not_active Application Discontinuation
- 2013-12-02 MX MX2015006754A patent/MX2015006754A/es unknown
- 2013-12-02 BR BR112015007312A patent/BR112015007312A2/pt not_active Application Discontinuation
- 2013-12-02 WO PCT/EP2013/075219 patent/WO2014086704A1/en active Application Filing
- 2013-12-02 EP EP13798352.4A patent/EP2925751A1/en not_active Withdrawn
- 2013-12-02 US US14/443,823 patent/US9296711B2/en not_active Expired - Fee Related
- 2013-12-02 KR KR1020157014595A patent/KR20150090100A/ko not_active Application Discontinuation
-
2015
- 2015-10-12 HK HK15109926.3A patent/HK1209123A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1209123A1 (en) | 2016-03-24 |
| CN104870444A (zh) | 2015-08-26 |
| EP2925751A1 (en) | 2015-10-07 |
| US9296711B2 (en) | 2016-03-29 |
| KR20150090100A (ko) | 2015-08-05 |
| MX2015006754A (es) | 2015-08-05 |
| CA2884711A1 (en) | 2014-06-12 |
| JP2016501212A (ja) | 2016-01-18 |
| RU2015122615A (ru) | 2017-01-10 |
| US20150307463A1 (en) | 2015-10-29 |
| WO2014086704A1 (en) | 2014-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014032053A2 (pt) | composto, composição farmacêutica, utilização de um composto, método para o tratamento de câncer e invenção | |
| BR112014008126A2 (pt) | composto, método para o tratamento, composição farmacêutica, utilização de um composto e invenção | |
| BR112014029404A2 (pt) | compostos , composição farmacêutica, utilização de um composto, método para o tratamento ou profilaxia do cancêr e invenção | |
| BR112015004489A2 (pt) | composto, composição farmacêutica, e, métodos para tratar um distúrbio proliferativo e para sintetizar um composto | |
| BR112015001830A2 (pt) | composto, uso de um composto, método para o tratamento ou profilaxia de câncer e invenção | |
| BR112015004547A8 (pt) | compostos, composição farmacêutica, uso de um composto e método para o tratamento ou melhoria do cãncer | |
| BR112014032105A2 (pt) | método para o tratamento de câncer | |
| BR112014029674A2 (pt) | composto, composição farmacêutica, método para o tratamento de uma doença, utilização de um composto, conjunto para o tratamento de uma condição mediada pela quinase pim e invenção | |
| DK2818482T3 (da) | Farmaceutisk sammensætning til behandling af cancer | |
| BR112014003681A8 (pt) | composto, composição farmacêutica, produto de combinação farmacêutica, uso de um composto, e, método para tratar doenças ou condições | |
| BR112013023175A2 (pt) | composto, inibidor, medicamento, agente anticâncer, composição farmacêutica, método para o tratamento de câncer, e, uso de um composto | |
| DK2824114T3 (da) | Farmaceutisk sammensætning til behandling af cancer | |
| BR112014007203A2 (pt) | composto, composição farmacêutica, método de tratamento, utilização de um composto, conjunto e invenção | |
| BR112012018951A2 (pt) | composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo | |
| BR112014031896A2 (pt) | composto, composição farmacêutica, e, método para o tratamento de um distúrbio | |
| BR112014010197A2 (pt) | composto, composição farmacêutica, método de tratamento de um distúrbio | |
| BR112014011671A2 (pt) | composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto | |
| BR112012018943A8 (pt) | medicamento e método para o tratamento e/ou prevenção de um câncer | |
| BR112015007214A8 (pt) | composto, método para a inibição da atividade da quinase, método para o tratamento, composição, utilização de um composto e invenção | |
| BR112014030416A2 (pt) | composto, métodos para a inibição da tankyrase 1 e para o tratamento do câncer, utilização de um composto, composição e invenção. | |
| BR112014028424A2 (pt) | compostos de pirimidina para o tratamento de câncer | |
| BR112012026570A2 (pt) | composto, composição farmacêutica, uso de um composto, método para o tratamento de um indíviduo e produto combinado | |
| BR112014032510A2 (pt) | composto, composição farmacêutica, método para tratar ou prevenir uma doença ou desordem, e, uso de um composto. | |
| BR112015000649A2 (pt) | compostos, composição farmacêutica, uso de um composto, método para tratar ou melhorar câncer e invenção | |
| BR112014016736A8 (pt) | composto, composição farmacêutica, método para tratamento, uso de um composto e invenção |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |